Drug Trial Radar · NCT01730534
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Last checked: Nov 19, 2026Latest source record: Dec 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17,190
Actual
Start
Apr 25, 2013
Primary completion
Sep 11, 2018
Study completion Sep 11, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
- First posted
- Nov 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mgDrug
Oral dose (od)
Placebo tabletDrug
Oral dose (od)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic StrokeTime frame: up to 5.2 years
- Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.Time frame: up to 5.2 years
Locations
805 sites in 34 countries. Site status is shown where the registry gives one.
Research Site
Alexander City, Alabama
Research Site
Athens, Alabama
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Mobile, Alabama
Research Site
Montgomery, Alabama
Research Site
Mesa, Arizona
Research Site
Mesa, Arizona
Research Site
Phoenix, Arizona
Research Site
Alhambra, California
Research Site
Bakersfield, California
Research Site
Greenbrae, California
Research Site
Huntington Park, California
Research Site
La Mesa, California
Research Site
Lomita, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
San Diego, California
Research Site
San Marino, California
Research Site
San Ramon, California
Research Site
Torrance, California
Research Site
Ventura, California
Research Site
Vista, California
Research Site
Fort Collins, Colorado
Research Site
Golden, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Bristol, Connecticut
Research Site
Norwalk, Connecticut
Research Site
Stamford, Connecticut
Research Site
Trumbull, Connecticut
Research Site
Waterbury, Connecticut
Research Site
Newark, Delaware
Research Site
Seaford, Delaware
Research Site
Wilmington, Delaware
Research Site
Washington D.C., District of Columbia
Research Site
Bradenton, Florida
Research Site
Chiefland, Florida
Research Site
Clearwater, Florida
Showing 40 of 805 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.